Abiopharma

Guardant Health, Inc. - Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

LifeMD to Participate in the BTIG Digital Health Forum

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

Calidi Biotherapeutics - Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC

CareDx - CareDx to Participate in Upcoming Investor Conferences

Esperion Announces New Data from CLEAR Outcomes Highlighting Value ofNEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health